| Identification | Back Directory | [Name]
Necitumumab | [CAS]
906805-06-9 | [Synonyms]
Necitumumab
IMC-11F8/LY301221
Necitumumab (anti-EGFR)
Research Grade Necitumumab(DHB86901) |
| Hazard Information | Back Directory | [Uses]
Necitumumab is a human IgG monoclonal antibody directed against EGFR. Necitumumab can be used for research of NSCLC, colorectal cancer, etc[1]. | [Clinical Use]
IgG1 monoclonal antibody:
Treatment of locally advanced or metastatic
epidermal growth factor receptor (EGFR) expressing
squamous non-small cell lung cancer | [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant use. | [Metabolism]
The elimination routes of necitumumab are only partially
documented, and involve degradation to peptides after
being internalised into its target cells, proteolysis within
the liver or the reticuloendothelial system, as well as
nonspecific endocytosis. | [References]
[1] Garnock-Jones KP. Necitumumab: First Global Approval. Drugs. 2016 Feb;76(2):283-9. DOI:10.1007/s40265-015-0537-0 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
|